IngredientsAlpha-naphthoflavone (ANF), also known as 7,8-benzoflavone, is a synthetic flavonoid belonging to the broader class of flavones. According to the Chemical Entities of Biological Interest (ChEBI) database, alpha-naphthoflavone is an extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. Its molecular formula is C₁₉H₁₂O₂, and it carries the CAS registry number 604-59-1. The compound is also indexed under PubChem CID 11790.
Common synonyms include: alpha-naphthoflavone, α-NF, ANF, 7,8-benzoflavone, and benzo(h)flavone. α-Naphthoflavone (αNF), a prototype flavone, is also known as 7,8-benzoflavone and is a modulator of the aryl hydrocarbon receptor (AhR) with both agonistic and antagonistic actions.
Naphthoflavone is a synthetic derivative of naturally occurring flavonoids. Although it is primarily used in research and certain commercial contexts in its synthetically produced form, naphthoflavone has been observed in Passiflora incarnata Linn. This identification in Passiflora incarnata (common passionflower) constitutes the primary natural botanical source documented in the peer-reviewed literature; however, the compound is overwhelmingly studied and used in its synthetic form rather than as an extract from this plant.
As a synthetic compound, alpha-naphthoflavone is an inhibitor of aromatase (EC 1.14.14.14). The structural relationship to naturally occurring flavones — which are widely distributed across plants in the Apiaceae, Lamiaceae, and Asteraceae families — reflects its design as a ring-extended analogue. Its immediate structural relatives in the naphthoflavone series include beta-naphthoflavone (β-NF or 5,6-benzoflavone), with which it shares a naphthalene-fused core but differs fundamentally in biological activity.
Alpha-naphthoflavone is commercially available primarily as a purified crystalline powder for biochemical research applications. The flavone can be recrystallized from ethanol or aqueous ethanol. It is also available dissolved in dimethyl sulfoxide (DMSO) for cell-based assays. Pharmacokinetic predictions based on computational models indicate high gastrointestinal absorption for ANF, making it potentially suitable for oral administration. No standardized pharmaceutical or dietary supplement formulation has been approved or widely marketed for ANF in isolation. Its use in supplement contexts is extremely limited compared to related naturally occurring flavones such as quercetin, luteolin, or apigenin.
Because alpha-naphthoflavone is a synthetic compound, it has no documented history of traditional or ethnobotanical use in any historical culture. There are no records of its use in Traditional Chinese Medicine, Ayurveda, European herbal traditions, or any other traditional healing system, as the compound was only synthesized in the modern era of organic chemistry and has been characterized biochemically from the mid-twentieth century onward.
Alpha-naphthoflavone (ANF) or 7,8-benzoflavone, a synthetic flavonoid, has been widely used in biochemical and biological studies concerning the mechanisms of action of chemical carcinogens. Its primary historical role has therefore been as a research tool in mechanistic toxicology and enzymology, rather than in any therapeutic tradition. To the extent that traditional use of Passiflora incarnata — the only plant in which naphthoflavone has been documented — is relevant, that use pertains to the whole plant and not to isolated naphthoflavone. Traditional applications of Passiflora incarnata include its use as a mild sedative and anxiolytic in Native American and later European folk medicine, but these uses are attributed to other constituents (primarily flavone glycosides and alkaloids) and cannot be attributed to ANF specifically.
Alpha-naphthoflavone belongs to the flavone subclass of flavonoids. Its scaffold consists of a chromone (benzo-γ-pyrone) backbone with a fused naphthalene ring system rather than the single benzene A-ring found in simple flavones. This bicyclic extension increases the compound's planarity and hydrophobicity relative to naturally occurring flavones, and is responsible for its enhanced affinity for the ligand-binding domains of certain receptors and enzymes. Naphthoflavone contains only two structural isomers, α-naphthoflavone and β-naphthoflavone, which facilitates the investigation of their distinct biological functions.
The most extensively documented and pharmacologically important mechanism of action for ANF involves its bidirectional modulation of the aryl hydrocarbon receptor (AhR). The aryl hydrocarbon receptor (AHR) was initially discovered as a cellular protein involved in mediating the detoxification of xenobiotic compounds. Extensive research in the past two decades has identified several families of physiological ligands and uncovered important functions of AHR in normal development and homeostasis.
Alpha-naphthoflavone (αNF) is a weak aryl hydrocarbon (Ah) receptor agonist and inhibits the induction of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. This dual behavior is highly concentration-dependent. ANF antagonizes AhR, blocking the expression of phase I and II genes at nanomolar concentrations, although it can agonize AhR at higher concentrations (10 μM). Mechanistically, it has been suggested that the Ah receptor antagonist activity is due to the formation of αNF–cytosolic Ah receptor complexes that fail to undergo transformation, a hypothesis consistent with data obtained using αNF concentrations from 10 to 1000 nM.
Studies in human MCF-7 breast cancer cells confirmed this antagonist activity directly. αNF inhibited 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 gene expression in MCF-7 human breast cancer cells and also decreased the accumulation of the nuclear [³H]TCDD–aryl hydrocarbon (Ah) receptor complex. Further, nuclear extracts from cells treated with 10⁻⁶ M αNF and incubated with a dioxin-responsive element (DRE, 26-mer) did not form a retarded band in a gel mobility shift assay, indicating that the αNF–AhR complex, while formed, is incapable of binding to genomic response elements and activating target gene transcription. These data confirm that αNF is an Ah receptor agonist and, based on the results of previous studies, exhibits partial antagonist activity via competition for receptor binding sites.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that promotes the expression of phase I and II xenobiotic chemical metabolizing enzyme genes, including the cytochrome P450 (CYP) isoforms CYP1A1 and CYP1A2. The Ah receptor mediates many of the toxic responses induced by polyhalogenated and polycyclic hydrocarbons (PAHs), which are ubiquitous environmental contaminants causing toxic responses in humans and wildlife.
ANF is one of the most potent and extensively characterized small-molecule modulators of the CYP1 family. α-Naphthoflavone inhibits CYP19 (aromatase), CYP1A1, CYP1A2, and CYP1B1, with IC₅₀ values of 500, 60, 6, and 5 nM, respectively, whereas it activates CYP3A4 (Kd = 7.4 μM).
CYP1A2 inhibition: Alpha-naphthoflavone (ANF) is bound to the recombinant P450 1A2 tightly and stabilizes an overall enzyme conformation. ANF is generally known as a competitive inhibitor of the enzyme; however, in tight-binding enzyme kinetics studies, ANF acts as a noncompetitive inhibitor in 7-ethoxycoumarin O-deethylation (Ki = 55.0 nM) but as a competitive inhibitor in 7-ethoxyresorufin O-deethylation (Ki = 1.4 nM). The nature of inhibition is thus substrate-dependent. Based on homology modeling studies, ANF is positioned to bind to a hydrophobic cavity next to the active site where it may cause a direct effect on substrate binding.
CYP1B1 inhibition: At low concentration — that is, 10 nM — alpha-naphthoflavone inhibits CYP1B1 activity by 80% and CYP1A1 activity by only 20%, which has made ANF a useful discriminating tool for researchers investigating CYP1B1 activity in tumor tissues. Cytochrome P450 1B1 (CYP1B1) has been recognized as an important target for cancer prevention and drug resistance reversal. ANF was a competitive tight-binding inhibitor of CYP1A1, CYP1A2, and CYP1B1.
CYP1A1 inhibition: ANF has been shown to inhibit benzo(a)pyrene metabolism by beta-naphthoflavone-induced rat liver microsomes but has no inhibitory effect on benzo(a)pyrene metabolism in phenobarbital-induced rat liver microsomes. The selectivity for certain P450 induction states reflects the compound's sensitivity to which P450 isoform is expressed in the tissue.
CYP3A4 activation: In a striking contrast to its inhibitory effects on the CYP1 family, ANF acts as an allosteric activator of CYP3A4. Researchers employed flash photolysis to probe the interaction of alpha-naphthoflavone with human cytochrome P450s 1A1 and 3A4, whose benzo[a]pyrene hydroxylation activities are respectively inhibited and stimulated by this compound. This flavonoid inhibited P450 1A1 binding to benzo[a]pyrene via a classical competitive mechanism. In contrast, alpha-naphthoflavone stimulated P450 3A4 by selectively binding and activating an otherwise inactive subpopulation of this P450. ANF is the heterotropic allosteric effector of CYP3A4 whose sequential metabolism of certain substrates is increased by ANF. ANF increases the formation rates for metabolites and perturbs metabolite ratios. Thus ANF has an allosteric effect on a kinetic branch point.
UDP-glucuronosyltransferase (UGT) interactions: Alpha-naphthoflavone markedly reduced UDP-glucuronosyltransferase activity with non-permeabilized microsomes from 3-methylcholanthrene-treated rats. Kinetic analysis indicated that the inhibitory effect of alpha-NF is competitive. These results suggest that a UGT isoform involved in certain glucuronidation reactions is interfered with by a CYP1A inhibitor via a mechanism dependent on the intact nature of microsomal membranes.
The synthetic flavonoid α-naphthoflavone was the most potent aromatase inhibitor among flavonoids tested, with an I₅₀ value of 0.5 μM. Three naturally occurring flavonoids — chrysin, flavone, and genistein 4'-methyl ether (biochanin A) — showed I₅₀ values of 4.6, 68, and 113 μM, respectively, demonstrating that ANF's bicyclic naphthalene structure confers substantially greater potency at the aromatase active site than naturally occurring monocyclic flavones.
ANF is also one of the most potent flavonoids that inhibit BCRP-mediated mitoxantrone efflux. BCRP is an important multidrug resistance protein because it confers cross-resistance to several structurally unrelated classes of cancer chemotherapeutic agents. ANF's inhibition of BCRP has been observed in vitro at concentrations overlapping with its CYP1B1 inhibitory range.
Alpha-naphthoflavone inhibits platelet aggregation in a concentration-dependent manner (5–20 μM), and at 5 and 10 μM it inhibits intracellular Ca²⁺ mobilization, phosphoinositide breakdown, and thromboxane A₂ formation stimulated by collagen in human platelets. In addition, α-NF at 5 and 10 μM markedly increased levels of cyclic GMP and cyclic GMP-induced vasodilator-stimulated phosphoprotein (VASP) Ser157 phosphorylation.
α-Naphthoflavone concentration-dependently induced pro-collagen type I protein expression and inhibited MMP-1 protein expression in both normal and UVB-irradiated human skin fibroblasts. SB431542 and SIS3 — inhibitors of TGF-β and Smad3, respectively — significantly alleviated α-NF-caused responses of MMP-1 and pro-collagen. α-NF promotes pro-collagen production and inhibits MMP-1 expression via the activation of a PI3K/Akt/Smad-3 pathway in normal and UVB-irradiated human skin fibroblasts, while TGF-β may play an important role in transducing this pathway.
Synthetic flavonoid α-naphthoflavone is classified as an AhR antagonist and has been shown to promote adipogenesis and lipid accumulation in 3T3-L1 cells in vitro. This finding is consistent with a role for AhR signaling in the regulation of adipocyte differentiation, and contrasts with the activity of the AhR agonist beta-naphthoflavone.
NF-κB is a pleiotropic transcription factor controlling many physiological functions adversely affected by PAHs, including immune suppression, thymus involution, hyperkeratosis, and carcinogenesis. Physical interaction and mutual functional repression between AhR and NF-κB have been demonstrated. This mutual repression may provide an underlying mechanism for many hitherto poorly understood PAH-induced toxic responses, and may also provide a mechanistic explanation for alteration of xenobiotic metabolism by cytokines. ANF's capacity to antagonize AhR therefore has indirect implications for NF-κB-regulated inflammatory and immune pathways.
The investigation of ANF in cancer is one of the most extensive areas of research, encompassing procarcinogen metabolism, CYP1-mediated carcinogenesis, drug resistance, and direct antiproliferative effects. All evidence in this area is preclinical (cell culture and rodent models); no human clinical trials have evaluated ANF for cancer prevention or treatment.
Procarcinogen metabolism and early research: Alpha-naphthoflavone inhibits the metabolism of 3,4-benzopyrene and 7,12-dimethylbenz(a)anthracene in hamster embryo cell cultures and protects the cells against the inhibition of cell multiplication by these carcinogens. This early finding, published in Science, established ANF as both an inhibitor of carcinogen-activating enzymes and a protective agent against procarcinogen toxicity in cell models.
Estrogen-induced mammary carcinogenesis: A significant animal study investigated whether ANF could inhibit estrogen-induced mammary carcinogenesis. This study was reported to be the first to demonstrate the inhibition of breast carcinogenesis by the estrogen metabolic inhibitor ANF in an animal model of estrogen-induced mammary carcinogenesis, and results suggested that estrogen metabolism and oxidant stress are critically involved in estrogen-induced breast carcinogenesis. This was a rodent study and cannot be extrapolated directly to humans.
CYP1B1-mediated drug resistance: CYP1B1 is overexpressed in a variety of malignant tumours and has been implicated in resistance to anticancer drugs. CYP1B1 can metabolically inactivate a structurally diverse array of anti-cancer drugs such as docetaxel, tamoxifen, and paclitaxel, leading to drug resistance. Because ANF is a potent CYP1B1 inhibitor, it has been studied extensively as a scaffold for drug-resistance reversal agents. Taking α-naphthoflavone as a lead, a series of trimethoxy-α-naphthoflavones were synthesized and evaluated for their inhibitory potency against CYP1B1 and selectivity over CYP1A1 and 1A2. Water-soluble naphthoflavone derivatives were obtained that could obviously eliminate docetaxel resistance caused by enhanced expression of CYP1B1 in MCF-7/1B1 cells. These results are in vitro only.
CYP1B1 activity in renal cell carcinoma: A study in renal cell carcinoma tissue used ANF as a diagnostic tool. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours, and studies have been elucidating a functional role for CYP1B1 in drug resistance. In this work, ANF served primarily as a pharmacological tool to dissect CYP1 enzyme contributions in tumour samples rather than as a therapeutic agent itself.
Caution — potential pro-carcinogenic activity: The relationship of ANF to carcinogenesis is bidirectional. Dietary α-naphthoflavone can contribute to carcinogenesis in the presence of synthetic estrogens. This finding indicates that the CYP-modulating and estrogenic activities of ANF may under certain conditions facilitate rather than prevent carcinogenesis. The evidence base for this concern comes from animal studies, and the magnitude and conditions of this risk in humans are not established.
Previous studies have demonstrated an association between neurological diseases and oxidative stress. Naphthoflavone is a synthetic derivative of naturally occurring flavonoids that serves an important role in the treatment and prevention of oxidative stress-related diseases. All evidence is from in vitro or animal models; no human clinical trials exist.
Protection of human neuroblastoma cells: A study applied α- and β-naphthoflavone individually and in combination to counteract the detrimental effects of oxidative stress on neurons in vitro. Neuronal SH-SY5Y cells were subjected to 20 µM H₂O₂, followed by exposure to 20 µM α-naphthoflavone and/or 10 µM β-naphthoflavone. Results indicated that α- and β-naphthoflavone effectively antagonized the apoptosis-promoting effect of H₂O₂ on neuronal SH-SY5Y cells. Co-treatment of α- and β-naphthoflavone reversed the H₂O₂-induced apoptosis rate elevation and cell viability reduction.
Conflicting effects in neuronal cells: Even though αNF was shown to antagonize H₂O₂-induced apoptosis in human neuroblastoma SH-SY5Y cells and βNF-induced apoptosis in mouse primary neuronal cells, it also exerted pro-apoptotic effects in human cervical cancer HeLa cells in an AhR-independent manner. Furthermore, a study in hippocampal HT22 neuronal cells found that blocking AHR in HT22 hippocampal neuronal cells significantly reduced α-naphthoflavone-induced endoplasmic reticulum stress and cell death, suggesting that at high concentrations or in certain cellular contexts, ANF may itself act as a neurotoxic agent through AhR-dependent ER stress pathways.
These contradictory findings illustrate that the neuroprotective versus neurotoxic effects of ANF are highly context-dependent and concentration-dependent, and that the existing in vitro evidence is insufficient to characterize any net protective effect in the human nervous system.
The aryl hydrocarbon receptor (AHR) may be a key player in the pathogenesis of NAFLD, and it can modulate the synthesis of CYP1A1 and TNF-α. CYP1A1 is a key enzyme of oxidative stress, TNF-α is involved in the formation of insulin resistance, and oxidative stress and insulin resistance are key factors for NAFLD formation. AHR may therefore participate in contributing to NAFLD by regulating CYP1A1 and TNF-α.
A study was designed to explore the hepatoprotective effect of ANF in high fat diet (HFD)-induced NAFLD mice and oleic acid-treated HepG2 hepatocytes. Mice were fed an HFD to induce NAFLD, HepG2 cells were exposed to oleic acid to induce hepatocyte injury, and ANF significantly reduced mouse and cellular liver damage compared to HFD-induced NAFLD and oleic acid-treated HepG2 hepatocytes. ANF treatment reduces liver damage by reducing reactive oxygen species and insulin resistance; data show that ANF inhibits the expression of AHR, CYP1A1, and TNF-α in NAFLD, and these findings suggest potential for further development as a therapeutic agent for NAFLD.
Inhibition of AhR activity with α-naphthoflavone showed attenuation of steatosis in both high-fat diet fed in vivo and oleic acid-treated HepG2 models of NAFLD. Alpha-naphthoflavone at doses of 80 and 160 mg/kg/day administered by gavage for 4 weeks has shown protective effects on NAFLD mice induced by a high-fat diet. All evidence for NAFLD is preclinical (animal models and cell lines); no human clinical data are available.
α-NF concentration-dependently (5–20 μM) inhibited platelet aggregation stimulated by agonists. At 5 and 10 μM, α-NF inhibited intracellular Ca²⁺ mobilization, phosphoinositide breakdown, and thromboxane A₂ formation stimulated by collagen in human platelets. In addition, α-NF markedly increased levels of cyclic GMP and cyclic GMP-induced VASP Ser157 phosphorylation. Protein kinase C activation was markedly inhibited by α-NF at 5 and 10 μM. However, α-NF at these concentrations did not reduce the electron spin resonance (ESR) signal intensity of hydroxyl radicals in collagen-activated platelets, suggesting that the antiplatelet mechanism operates through the phospholipase C / cyclic GMP axis rather than direct radical scavenging.
These studies used human platelets in vitro (ex vivo laboratory experiments) and were published in the Journal of Agricultural and Food Chemistry. They establish a plausible mechanistic basis but do not constitute clinical evidence of cardiovascular benefit. The concentrations required (5–20 μM) are considerably higher than those achievable through conventional dietary flavone intake, and no in vivo or human clinical data on ANF's antiplatelet effects have been published.
α-Naphthoflavone concentration-dependently induced pro-collagen type I protein expression and inhibited MMP-1 protein expression in both normal and UVB-irradiated human skin fibroblasts. MMP-1 (matrix metalloproteinase-1) is a key enzyme responsible for the degradation of dermal collagen and is implicated in photoaging and intrinsic skin aging. LY294002 (a PI3K inhibitor) reverses α-NF-induced ERK, Akt, and Smad-3 activation, pro-collagen synthesis, and α-NF-suppressed AP-1 activation. ERK inhibition was not involved in pro-collagen generation and MMP-1 inhibition. The study concluded that α-NF promotes pro-collagen production and inhibits MMP-1 expression via the activation of a PI3K/Akt/Smad-3 pathway.
This work was carried out in primary human skin fibroblast cell cultures, both untreated and exposed to UVB irradiation — a model of photoaging. The evidence is in vitro only, published in Experimental Dermatology (2012), and has not been reproduced in human subjects.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that, besides mediating toxic responses, may have a central role in ovarian physiology. Beta-naphthoflavone amplifies the co-mitogenic actions of FSH and 17β-estradiol on granulosa cells in a dose-dependent manner; this amplification was even greater in cells overexpressing the AHR and was reversed by co-treatment with the AHR antagonist alpha-naphthoflavone, suggesting that this effect is mediated by the AHR. Alpha-naphthoflavone inhibited dose-dependently the mitogenic actions of FSH and 17β-estradiol.
These results indicate that ANF can modulate gonadotropin- and estrogen-driven cell proliferation in ovarian granulosa cells by blocking AhR-mediated amplification. This research has been conducted in cell culture models (in vitro) and has not been extended to human clinical investigations.
ANF has been investigated as a scaffold for developing inhibitors of aminoglycoside phosphotransferase APH(3')-IIIa, a resistance enzyme produced by Enterococcus faecalis. This research treated ANF primarily as a chemical scaffold for rational drug design in the context of antibiotic resistance rather than as a direct antimicrobial agent itself. The evidence is entirely computational (in silico molecular docking) and in vitro, and is preliminary in nature.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has been shown to regulate adipogenic factors and is involved in the induction of detoxifying enzymes such as cytochrome P450. Synthetic flavonoid α-naphthoflavone is classified as an AhR antagonist and has been shown to promote adipogenesis and lipid accumulation in 3T3-L1 cells in vitro. This finding is notable because it indicates a pro-adipogenic effect of AhR inhibition, potentially relevant to understanding metabolic consequences of AhR modulation, though this evidence is restricted to in vitro cell models.
No standardized human dosage for alpha-naphthoflavone exists, as no human clinical trials or approved therapeutic formulations have been established. The following represent doses used in experimental research settings only:
A toxicity analysis conducted using the ProTox-II web server reveals that ANF is not hepatotoxic, immunotoxic, or mutagenic. However, it does exhibit carcinogenic and cytotoxic potential. These are in silico predictions and should be considered indicative rather than definitive; they have not been validated with comprehensive formal toxicological testing in the published peer-reviewed literature as of available evidence.
Dietary α-naphthoflavone can contribute to carcinogenesis in the presence of synthetic estrogens. This is a significant and source-backed safety concern arising from animal and mechanistic studies. The co-carcinogenic potential in an estrogenic environment suggests that ANF cannot be assumed to be purely protective against cancer in all contexts.
ANF's ability to cross the blood–brain barrier (BBB) could lead to adverse effects on the central nervous system. Consistent with this concern, cell-based research found that blocking AHR in HT22 hippocampal neuronal cells significantly reduced alpha-naphthoflavone-induced ER stress and cell death, indicating that high-dose ANF exposure can activate toxic ER stress pathways in hippocampal neurons. Both the agonist (βNF) and antagonist (αNF) of AhR enhanced LDH release and caspase-3 activity stimulated by triclosan in mouse primary cortical neurons. This study was the first to show that co-treatment of cells with triclosan and αNF potentiated LDH release compared to treatment with triclosan alone. These findings indicate potential synergistic neurotoxicity with certain environmental contaminants.
ANF's powerful modulation of multiple CYP enzymes creates substantial potential for pharmacokinetic drug interactions. ANF has the potential to inhibit CYP1A2 and CYP2C9, enzymes responsible for the metabolism of several drugs, and consequently could generate interactions with substances metabolized by these cytochromes.
The simultaneous inhibition of CYP1A1, CYP1A2, and CYP1B1 alongside the allosteric activation of CYP3A4 creates a complex and potentially unpredictable interaction profile with pharmaceutical drugs. The anticarcinogenicity of some flavonoids has been attributed to modulation of the cytochrome P450 enzymes, which metabolize procarcinogens to their activated forms. However, the mechanism by which flavonoids inhibit some P450-mediated activities while activating others is a longstanding, intriguing question. The activation of CYP3A4 by ANF is particularly relevant because CYP3A4 is responsible for over 50% of oxidative drug metabolism due to its high expression levels in the liver and gut. Any significant CYP3A4 activation could thereby accelerate the metabolism and reduce the efficacy of a broad range of co-administered pharmaceuticals.
CYP1B1 can metabolically inactivate structurally diverse anti-cancer drugs such as docetaxel, tamoxifen, and paclitaxel, leading to drug resistance. While ANF's potent inhibition of CYP1B1 could theoretically reverse this resistance, the compound's simultaneous interaction with CYP3A4, BCRP, and aromatase makes its net pharmacological effect in patients receiving chemotherapy highly unpredictable. No human studies have evaluated ANF's safety or efficacy in combination with oncological treatments.
In studies of hepatic tissue, more microsomal lipid peroxidation was generated when incubated with the CYP1A inhibitor alpha-naphthoflavone, suggesting that inhibition of CYP1A enzymes in the context of altered hepatic preneoplastic foci may paradoxically increase oxidative stress rather than reduce it.
No human clinical trials, formal pharmacokinetic studies in humans, or established safe dose ranges in humans have been published for alpha-naphthoflavone. The compound's safety profile in humans is therefore entirely unknown from a direct experimental standpoint. Computational models predict high gastrointestinal absorption of ANF, making it potentially suitable for oral administration, but this remains unvalidated in vivo in humans. The gap between in vitro/rodent pharmacology and human safety represents a critical limitation of the entire ANF literature.
The table below summarizes the breadth and quality of evidence for alpha-naphthoflavone across its investigated applications:
Health conditions that Alpha-naphthoflavone may help support.
Body systems that Alpha-naphthoflavone may help support.
Go back